The investigators are doing this research study to assess the percentage of patients receiving stem cell transplantation for the type of blood cancer you have. They want to know how many patients get a transplant and why some patients do get a transplant while others do not. Also they want to explore why some patients elect not to undergo stem cell transplantation, when it is recommended by their physicians.
Patients with newly diagnosed or relapsed acute leukemia. Patients undergoing reinduction due to primary induction failure are also eligible. Patients with acute leukemia will be enrolled to Arm A
Clinically significant cytopenia of at least 2 cell lines affected; Hgb<10,
Platelet<100,000, absolute neutrophil count<1000
Bone marrow blasts >5% and any level of circulating blasts
Patients with polycythemia vera (PV) and essential thrombocytosis (ET)
Patients with acute leukemia and MDS or MPN who are treated inpatient or outpatient by the Leukemia Service for induction or re-induction therapy (acute leukemia) or initiation of therapy (for MDS or MPN) will be seen by the Adult BMT Service.
Cohort
Prospective
assessments
Other interventionAll laboratory assessments performed on this study represent standard of care at our institution. HLA allele typing is performed by the center's HLA laboratory according to standard typing procedures.
number of patients who proceed to transplant
determine whether an individual patient proceeded to HCT when he or she was considered eligible (based on NCCN guidelines.
Click on the lead sponsor to view all of their trials.
